Drug Trial Radar · NCT02001623
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
Last checked: Nov 20, 2026Latest source record: Dec 29, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
195
Actual
Start
Nov 30, 2013
Primary completion
May 2, 2019
Study completion May 2, 2019
Sponsor
- Lead sponsor
- Seagen Inc.Pfizer (PFE)
- Sponsor type
- Industry
- Collaborators
- Genmab
- First posted
- Dec 5, 2013
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the trial is to establish the tolerability of HuMax-TF-ADC in a mixed population of patients with specified solid tumors.
Conditions
- Ovary Cancer
- Cervix Cancer
- Endometrium Cancer
- Bladder Cancer
- Prostate Cancer (CRPC)
- Esophagus Cancer
- Lung Cancer(NSCLC)
- Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Interventions
Tisotumab Vedotin (HuMax-TF-ADC)Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Escalation Part: Evaluation of Treatment-Emergent Adverse EventsTime frame: Treatment emergent adverse events are reported from Day 1 to 30 days after dosing. The treatment duration ranged from 1 to 249 days in the dose escalation part.
- Dose Expansion Part: Evaluation of Treatment-Emergent Adverse EventsTime frame: Treatment emergent adverse events are reported from Day 1 to 30 days after dosing. The treatment duration ranged from 1 to 325 days in the dose expansion part.
Locations
29 sites in 5 countries. Site status is shown where the registry gives one.
University of California Irvine Medical Center (UCIMC)
Orange, California
Yale Cancer Center
New Haven, Connecticut
University of Miami
Miami, Florida
University Gynecologic Oncology
Atlanta, Georgia
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada
Sarah Cannon Research Institute
Nashville, Tennessee
MD Anderson Cancer Center
Houston, Texas
University of Virginia
Charlottesville, Virginia
Saint-Luc University Hospital
Brussels, Belgium
CHU de Liège
Liège, Belgium
CHU UCL Namur - Sainte Elisabeth
Namur, Belgium
Universitair Ziekenhuis Antwerpen
Edegem, Antwerpen, Belgium
Universitair Ziekenhuis Leuven
Leuven, Flemish Brabant, Belgium
Grand Hôpital de Charleroi
Charleroi, Hainaut, Belgium
Centre Hospitalier Universitaire Ambroise Paré
Mons, Hainaut, Belgium
CHU UCL Namur - site Godinne
Yvoir, Namur, Belgium
Rigshospitalet, Copenhagen University Hospital
Copenhagen, Denmark
Herlev and Gentofte Hospital
Herlev, Denmark
Lungemedicinska Kliniken
Linköping, Sweden
Karolinska Universitetssjukhuset
Stockholm, Solna, Sweden
Beatson Cancer Centre
Glasgow, United Kingdom
Guys hospital
London, United Kingdom
The Christie NHS Foundation Trust
Manchester, United Kingdom
The Leeds Teaching Hospitals NHS Trust
Leeds, England, United Kingdom
University College London Hospitals
London, England, United Kingdom
Sarah Cannon Research Institute - London
London, England, United Kingdom
Newcastle Hospitals NHS Foundation Trust
Newcastle upon Tyne, Newcastle, United Kingdom
The Royal Marsden NHS Foundation Trust
Sutton, Surrey, United Kingdom
Velindre NHS Trust
Cardiff, Wales, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.